NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx has received CE marking for an assay to detect resistant strains of Mycoplasma genitalium, the company announced today.

The ResistancePlus MG assay detects M. genitalium as well as mutations in the bacterium's 23S rRNA that confer resistance to the macrolide drug azithromycin.

"As with the better known STD, gonorrhea, M. genitalium has developed serious treatment challenges because of the recent rise of antibiotic resistance," Colin Denver, SpeeDx's CEO, noted in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.